{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:31:42Z","timestamp":1792816302205,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Failure to detect non\u2010ABO blood group alloantibodies places patients at risk for hemolytic reactions. Suboptimal alloantibody detection could result from posttransfusion testing performed too early, too late, or not at all. Testing performed too early may precede antibody induction, while testing performed too late could miss antibodies that have evanesced. Taking these factors into account, our goal was to determine the percentage of alloantibodies detected with real\u2010world testing practices.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>The alloantibody detection rate in a general hospital setting was determined based on the frequency and timing of antibody testing after red blood cell (RBC) transfusions and rates of antibody induction and evanescence. Intervals to follow up testing after RBC transfusions (n\u00a0=\u00a0561 RBC units in 100 random patients) were determined retrospectively. Best\u2010fit lines and equations for antibody induction and evanescence were computed on previously published data.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Nearly half (271\/561; 48.3%) of RBC infusions had either no follow\u2010up antibody screen or testing too soon (&lt;30 days) after transfusion to detect alloimmunization. Of the remaining RBC units, 10.3% (58\/561) had follow\u2010up testing 30 to 112 days posttransfusion, 28.7% (161\/561) were followed up at more than 112 days, and 12.7% (71\/561) were tested at both 30 to 112 days and more than 112 days. By inputting these timing data into best\u2010fit line equations for antibody induction and evanescence, we calculated an alloantibody detection rate of 31.6%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Posttransfusion antibody testing was inadequately timed for optimal alloantibody detection. Real\u2010world compatibility testing was predicted to detect less than one\u2010third of non\u2010ABO antibodies, thereby exposing patients to risks of mismatched transfusion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.13704","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T12:43:03Z","timestamp":1468068183000},"page":"2662-2667","source":"Crossref","is-referenced-by-count":58,"title":["Detection rate of blood group alloimmunization based on real\u2010world testing practices and kinetics of antibody induction and evanescence"],"prefix":"10.1111","volume":"56","author":[{"given":"Gary","family":"Stack","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine Service VA Connecticut Healthcare System West Haven Connecticut"},{"name":"Department of Laboratory Medicine Yale University School of Medicine New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Tormey","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine Service VA Connecticut Healthcare System West Haven Connecticut"},{"name":"Department of Laboratory Medicine Yale University School of Medicine New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1978.18178118550.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2014.04.008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13339"},{"key":"e_1_2_8_5_1","unstructured":"Transfusion\/donation fatalities [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; last updated2015Dec 12 [cited 2016 Feb 22]. Available from:http:\/\/www.fda.gov\/biologicsbloodvaccines\/safetyavailability\/reportaproblem\/transfusiondonationfatalities\/default.htm."},{"key":"e_1_2_8_6_1","unstructured":"U.K. Serious Hazards of Transfusion (SHOT) Steering Group.SHOT annual reports and summaries [Internet]. Manchester (UK): SHOT Office; [cited2016Feb 22]. Available from:http:\/\/www.shotuk.org\/shot-reports\/."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1996.7140216.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5696.593"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb07239.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP47QAAXTOZEKJ"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28288179022.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.34294143938.x"},{"key":"e_1_2_8_13_1","first-page":"225","article-title":"The persistence of red cell alloantibodies","volume":"6","author":"Reverberi R.","year":"2008","journal-title":"Blood Transfus"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.7.1431.1431"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40091127.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02014.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20120051"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01815.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.00106"},{"key":"e_1_2_8_20_1","unstructured":"Quest Diagnostics.What is six sigma quality at Quest Diagnostics? [Internet]. 2000\u20102016 [cited2016Mar 25]. Available from:http:\/\/www.questdiagnostics.com\/home\/about\/operations\/quality\/six-sigma.html."},{"key":"e_1_2_8_21_1","first-page":"42","article-title":"Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993","volume":"119","author":"Hoeltge GA","year":"1995","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1974.tb02731.x"},{"key":"e_1_2_8_23_1","first-page":"254","article-title":"Alloimmunization following blood transfusion","volume":"113","author":"Walker RH","year":"1989","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41111413.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.13704","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.13704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:55:32Z","timestamp":1695563732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.13704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/trf.13704"],"URL":"https:\/\/doi.org\/10.1111\/trf.13704","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}